Pipeline
These networks have granted us access to large-scale GMP cell manufacturing facilities and reaching out to patients from diverse backgrounds.
BioSyngen has partnered with an extensive hospital network as well as received support from both the public sector and private enterprises in China and Singapore.
PRODUCT
INDICATIONS
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
BRG01
First-in-Class
Worldwide exclusive license
Nasopharyngeal cancer
EBV+ Hematologic malignancies
BRL03
Best-in-Class
Worldwide exclusive license
Nasopharyngeal cancer
Super-T (BGT007)
First-in-Class
CRC, GC, EC&PDAC
MSE-T (BST008)
Best-in-Class
HCC (cover all subtypes)
Multi-specific antibodies
First-in-Class
Multiple solid tumors
Allo-cel
First-in-Class
Multiple solid and liquid tumors
Worldwide exclusive license
First-in-Class
Nasopharyngeal cancer
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
EBV+ Hematologic malignancies
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
Worldwide exclusive license
Best-in-Class
Nasopharyngeal cancer
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
First-in-Class
CRC, GC, EC&PDAC
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
Best-in-Class
HCC (cover all subtypes)
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
First-in-Class
Multiple solid tumors
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
First-in-Class
Multiple solid and liquid tumors
PRE-CLINICAL
IIT/PHASE 1
PHASE 2
Copyright © 2022
Biosyngen Pte. Ltd.
Copyright © 2022 Biosyngen Pte. Ltd.
MENU
